Oleclumab (MEDI9447) epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) novel combination study

Study identifier:D6070C00004

ClinicalTrials.gov identifier:NCT03381274

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects with Previously Treated Advanced EGFRm NSCLC

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Osimertinib, AZD4635

Sex

All

Actual Enrollment

43

Study type

Interventional

Age

18 Years - 101 Years

Date

Study Start Date: 08 May 2018
Primary Completion Date: 24 May 2021
Estimated Study Completion Date: 15 Jan 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria